Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Champions Oncology (CSBR – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $6.41.
Hewitt covers the Healthcare sector, focusing on stocks such as Apyx Medical, Omnicell, and Repligen. According to TipRanks, Hewitt has an average return of 10.2% and a 45.99% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Champions Oncology with a $10.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
CSBR market cap is currently $86.91M and has a P/E ratio of -27.86.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Read More on CSBR:
